Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript May 2, 2024 Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.16. PBYI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Camilla, […]